Andrew Hill

4 ta ish

Azienda Unita' Sanitaria Locale Di Modena

1. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

   James Larkin, Vanna Chiarion‐Sileni, René González +28

   MaqolaOAOchiq kirish20153 iqtibos

   ABIABI:AkademIndex/2026.other.170114

2. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

   Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong +17

   MaqolaOAOchiq kirish20183 iqtibos

   ABIABI:AkademIndex/2026.other.241935

3. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

   Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González +30

   MaqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.082822

4. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

   Michael J. Overman, Ray McDermott, Joseph L. Leach +13

   MaqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.241933